Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas
This study is currently recruiting participants.
Verified by Pennington Biomedical Research Center, June 2008
Sponsors and Collaborators: Pennington Biomedical Research Center
Lipothera
Information provided by: Pennington Biomedical Research Center
ClinicalTrials.gov Identifier: NCT00624416
  Purpose

The purpose of this study is to test whether injected medications will increase the amount of fat released by a fat cell. We will compare prednisolone (a synthetic cortisone) combined with isoproterenol (a drug given for asthma) versus using isoproterenol alone. We will also test if injections of isoproterenol and prednisolone will shrink the size of lipomas, which are benign fatty tumors.


Condition Intervention Phase
Lipoma
Drug: Isoproterenol;Prednisolone
Phase I
Phase II

Drug Information available for: Prednisolone 6-Methylprednisolone Depo-medrol Medrol veriderm Methylprednisolone Methylprednisolone hemisuccinate Methylprednisolone Sodium Succinate Prednisolone acetate Prednisolone sodium phosphate Prednisolone Sodium Succinate Corticosteroids Isoproterenol Isoproterenol hydrochloride Isoproterenol sulfate Isoetharine Isoetharine hydrochloride Isoetharine mesylate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas

Further study details as provided by Pennington Biomedical Research Center:

Primary Outcome Measures:
  • Lipoma volume at the end of the treatment period compared to baseline. [ Time Frame: Weekly ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: October 2007
Estimated Study Completion Date: December 2008
Estimated Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Drug: Isoproterenol;Prednisolone
Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.

Detailed Description:

Lipomas are non-cancerous fatty tumors that occur under the skin and make a bump that can be easily felt and often seen. The current treatment for lipomas is surgery. Isoproterenol, a medication used for the treatment of asthma and approved for injection under the skin, is known to cause fat cells to give up their fat. The fat cells become resistant to isoproterenol with repeated use. Prednisolone, a synthetic cortisone medication used to treat immune problems like allergy and approved for injection under the skin, keeps the fat cells from becoming resistant to isoproterenol. It is not known, if the fat cells in lipomas act like other fat cells or if the combination of isoproterenol and prednisolone injections would shrink lipomas without surgery. This study is designed to test this possibility.

Subjects will have a screening visit, 2 microdialysis visits a week apart, 20 treatment visits 5 days per week for 4 weeks, and up to 12 follow-up visits a year after treatment visits. During screening, subjects will have a history, physical exam, blood testing, electrocardiogram and a pregnancy testing if female with reproductive capacity. The first microdialysis visit will consist of placing two microdialysis catheters under the skin after the area is numbed. One microdialysis catheter will be in the lipoma and the other under the skin 2 inches away. The microdialysis catheter will connect to a pump, isoproterenol will be infused and the amount of fat breakdown measured. One week later prednisolone will be injected into the lipoma and under the skin 2 inches away. The microdialysis visit will be repeated 24 hours later.

Treatment will consist of injecting the lipoma 5 days a week with a mixture of isoproterenol and prednisolone in the Pennington clinic as a diabetic would inject insulin. Each week the blood pressure, pulse and lipoma will be measured and subjects will be asked how they feel. At the end of the treatment period the physical examination, blood test and electrocardiogram will be repeated.

The insertion of the microdialysis probes under the skin into the fat tissue could be uncomfortable, but numbing medication will be injected first to prevent this problem. At higher doses, isoproterenol could lower blood pressure and increase pulse rate. This should not happen at the doses used, but blood pressure and pulse will be monitored throughout the study. Prednisolone, at higher doses, could decrease the body's production of cortisone. This should not happen at the doses being used, but cortisone in the body will be measured during the trial. Blood tests involve the discomfort of a needle going through the skin of the arm, possible bruising and rarely fainting or infection. Trained technicians and sterile needles will minimize these risks.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • You are a man or a woman between the ages of 18-60, inclusive.
  • You have a body mass index (BMI) between 20 and less than 40 kg/m2. BMI is a number calculated from your height and weight.
  • You have a lipoma (a benign fatty tumor) that is 1 inch or more in diameter under the skin of your abdomen or on another area of your body that is easily accessible to study (such as the thigh).
  • You have not gained or lost more than 11 pounds in the last 3 months.
  • Your exercise routine has been stable for the last 3 months or you are sedentary. Sedentary means you do less than 60 minutes of exercise per week.

Exclusion Criteria:

  • You have a history of heart or blood vessel disease.
  • Your blood pressure is above 140/90 mmHg.
  • You have type 1 diabetes.
  • You have a history of kidney or liver disease.
  • You have thyroid disease that has not been treated.
  • You are a smoker.
  • You use a Beta-2 (B2) adrenergic stimulator (a type of drug used to treat asthma), a beta adrenergic blocker (a type of drug used to treat blood pressure) or glucocorticoid medications (a type of drug used to treat immune system disease).
  • You have a problem with alcoholism or other substance abuse.
  • You are pregnant or breast feeding.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00624416

Contacts
Contact: Aubrey Windham, B.S. 225-763-0920 aubrey.windham@pbrc.edu
Contact: Anne Chatellier, RN,CCRC 225-763-2676 anne.chatellier@pbrc.edu

Locations
United States, Louisiana
Pennington Biomedical Research Center Recruiting
Baton Rouge, Louisiana, United States, 70808
Contact: Frank Greenway, M.D.     225-763-2576     frank.greenway@pbrc.edu    
Contact: Leanne Redman, Ph.D.     225-763-0947     leanne.redman@pbrc.edu    
Principal Investigator: Leanne Redman, Ph.D.            
Sub-Investigator: Frank Greenway, M.D.            
Pennington Biomedical Research Center Recruiting
Baton Rouge, Louisiana, United States, 70808
Contact: Aubrey Windham, B.S.     225-763-0920     aubrey.windham@pbrc.edu    
Contact: Anne Chatellier, R.N.     225-763-2676     anne.chatellier@pbrc.edu    
Principal Investigator: Leanne Redman, Ph.D.            
Sponsors and Collaborators
Pennington Biomedical Research Center
Lipothera
Investigators
Principal Investigator: Leanne Redman, Ph.D. Pennington Biomedical Research Center
Study Director: Frank Greenway, M.D. Pennington Biomedical Research Center
  More Information

Responsible Party: Pennington Biomedical Research Center ( Leanne Redman, Ph.D. )
Study ID Numbers: PBRC27015
Study First Received: February 15, 2008
Last Updated: June 20, 2008
ClinicalTrials.gov Identifier: NCT00624416  
Health Authority: United States: Institutional Review Board

Keywords provided by Pennington Biomedical Research Center:
Lipoma
Isoproterenol
Prednisolone
Microdialysis

Study placed in the following topic categories:
Neoplasms, Connective and Soft Tissue
Methylprednisolone
Lipoma
Prednisolone
Methylprednisolone acetate
Prednisolone acetate
Isoproterenol
Methylprednisolone Hemisuccinate

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Respiratory System Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Antineoplastic Agents
Cardiotonic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Neuroprotective Agents
Hormones
Adrenergic Agonists
Therapeutic Uses
Neoplasms by Histologic Type
Adrenergic beta-Agonists
Antineoplastic Agents, Hormonal
Sympathomimetics
Gastrointestinal Agents
Anti-Asthmatic Agents
Cardiovascular Agents
Protective Agents
Glucocorticoids
Pharmacologic Actions
Neoplasms
Autonomic Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Bronchodilator Agents
Neoplasms, Adipose Tissue

ClinicalTrials.gov processed this record on January 16, 2009